Guizhou Sanli Pharmaceutical Co Ltd (603439) — Cash Flow Quality Index

Latest as of June 2025: 0.78x

Guizhou Sanli Pharmaceutical Co Ltd (603439) has a Cash Flow Quality Index of 0.78x as of June 2025. Operating cash flow of CN¥32.03 Million is below net income of CN¥41.11 Million, suggesting accrual-heavy earnings not yet converted to cash. Also explore Guizhou Sanli Pharmaceutical Co Ltd asset portfolio for the complete picture of this company's asset base.

Cash Flow Quality Index

0.78x
Operating CF / Net Income

Operating Cash Flow

CN¥32.03 Million
CNY

Net Income

CN¥41.11 Million
CNY

Data as of

Jun 2025
Most recent filing

Guizhou Sanli Pharmaceutical Co Ltd Cash Flow Quality Index (2013–2024)

Historical Cash Flow Quality Index for Guizhou Sanli Pharmaceutical Co Ltd across 12 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check 603439 goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.

Annual Cash Flow Quality Index for Guizhou Sanli Pharmaceutical Co Ltd (2013–2024)

Year-by-year earnings quality comparison for Guizhou Sanli Pharmaceutical Co Ltd. For live market cap and the full company financial profile, see 603439 stock market capitalisation.

Year Quality Index Operating CF (CNY) Net Income YoY Change
2024 0.38x CN¥107.07 Million CN¥279.84 Million ▼ -59.5%
2023 0.95x CN¥276.70 Million CN¥292.70 Million ▼ -38.1%
2022 1.53x CN¥293.29 Million CN¥191.94 Million ▲ +46.5%
2021 1.04x CN¥155.04 Million CN¥148.60 Million ▲ +55.0%
2020 0.67x CN¥63.25 Million CN¥93.95 Million ▼ -22.9%
2019 0.87x CN¥116.24 Million CN¥133.07 Million ▲ +28.1%
2018 0.68x CN¥75.35 Million CN¥110.48 Million ▲ +4.0%
2017 0.66x CN¥57.47 Million CN¥87.63 Million ▲ +39.9%
2016 0.47x CN¥35.10 Million CN¥74.88 Million ▼ -25.9%
2015 0.63x CN¥33.28 Million CN¥52.61 Million ▲ +3154.9%
2014 0.02x CN¥563.46K CN¥28.99 Million ▼ -98.7%
2013 1.55x CN¥30.09 Million CN¥19.37 Million
Cash Flow Quality Index = Operating Cash Flow / Net Income. Ratios above 1.0x indicate cash-backed earnings.